Algernon Pharmaceuticals has received approval to conduct a Phase 1 clinical study of an intravenous formulation (IVF) of DMT for the treatment of stroke in the...
Small Pharma has received approval for an interaction study between the company’s lead N, N-dimethyltryptamine (DMT) candidate – SPL026 – and serotonin reuptake inhibitors (SSRIs).
Algernon Pharmaceuticals is working to complete an intravenous formulation (IVF) that will be used in its Phase 1 DMT study investigating the compound’s efficacy as a...
Pharmadrug has announced it is advancing its opthalmology programme with the selection of its lead DMT analogue as a potential treatment for primary open angle glaucoma...
The first patient has now been enrolled on to the Entheon Biomedical Phase 1 Study of DMT.
PharmaDrug has generated data showing that DMT-analogues could provide a new treatment for primary open angle glaucoma.
A Phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of DMT will further research into the compound’s therapeutic potential.
Psychedelics manufacturer Psygen has received the dealer’s license for LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline.
Return Health is exploring psychedelic derivatives for the treatment of dementia.
In a bid to help bring DMT and 5-MeO-DMT to patients, Biomind Labs has completed the development of its novel nasal gel delivery system.